Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer_journal/probability-of-achieving-glycemic-control-with-basal-insulin-in-sS0BKiEa3j
References (40)
-
(Dalal MR, Grabner M, Bonine N, Stephenson JJ, DiGenio A, Bieszk N. Are patients on basal insulin attaining glycemic targets? Characteristics and goal achievement of patients with type 2 diabetes mellitus treated with basal insulin and physician-perceived barriers to achieving glycemic targets. Diabetes Res Clin Pract. 2016;121:17–26.)
Dalal MR, Grabner M, Bonine N, Stephenson JJ, DiGenio A, Bieszk N. Are patients on basal insulin attaining glycemic targets? Characteristics and goal achievement of patients with type 2 diabetes mellitus treated with basal insulin and physician-perceived barriers to achieving glycemic targets. Diabetes Res Clin Pract. 2016;121:17–26.Dalal MR, Grabner M, Bonine N, Stephenson JJ, DiGenio A, Bieszk N. Are patients on basal insulin attaining glycemic targets? Characteristics and goal achievement of patients with type 2 diabetes mellitus treated with basal insulin and physician-perceived barriers to achieving glycemic targets. Diabetes Res Clin Pract. 2016;121:17–26., Dalal MR, Grabner M, Bonine N, Stephenson JJ, DiGenio A, Bieszk N. Are patients on basal insulin attaining glycemic targets? Characteristics and goal achievement of patients with type 2 diabetes mellitus treated with basal insulin and physician-perceived barriers to achieving glycemic targets. Diabetes Res Clin Pract. 2016;121:17–26.
-
S. Harris, J. Kapor, C. Lank, A. Willan, T. Houston (2010)
Clinical inertia in patients with T2DM requiring insulin in family practice.Canadian family physician Medecin de famille canadien, 56 12
-
X. Cai, Xueying Gao, Wenjia Yang, L. Ji (2017)
Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysisExpert Opinion on Pharmacotherapy, 18
-
E. Heintjes, T. Thomsen, F. Beest, T. Christensen, R. Herings (2010)
Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetesAdvances in Therapy, 27
-
V. Valentine, J. Goldman, J. Shubrook (2017)
Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 DiabetesDiabetes Therapy, 8
-
(Kostev K, Dippel FW, Rathmann W. Glycemic control after initiating basal insulin therapy in patients with type 2 diabetes: a primary care database analysis. Diabetes Metab Syndr Obes. 2015;8:45–8.)
Kostev K, Dippel FW, Rathmann W. Glycemic control after initiating basal insulin therapy in patients with type 2 diabetes: a primary care database analysis. Diabetes Metab Syndr Obes. 2015;8:45–8.Kostev K, Dippel FW, Rathmann W. Glycemic control after initiating basal insulin therapy in patients with type 2 diabetes: a primary care database analysis. Diabetes Metab Syndr Obes. 2015;8:45–8., Kostev K, Dippel FW, Rathmann W. Glycemic control after initiating basal insulin therapy in patients with type 2 diabetes: a primary care database analysis. Diabetes Metab Syndr Obes. 2015;8:45–8.
-
W. Strain, Xavier Cos, Michael Hirst, Sergio Vencio, Viswanathan Mohan, Zoltán Vokó, Daisuke Yabe, Matthias Blüher, P. Paldánius (2014)
Time to do more: addressing clinical inertia in the management of type 2 diabetes mellitus.Diabetes research and clinical practice, 105 3
-
L. Berard, M. Bonnemaire, Marie Mical, S. Edelman (2017)
Insights into optimal basal insulin titration in type 2 diabetes: Results of a quantitative surveyDiabetes, Obesity & Metabolism, 20
-
Qian Rong-l (2013)
A better comprehension of “Management of Hyperglycemia in Type 2 Diabetes:A Patient-Centered Approach—Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)” -
(2017)
6. Glycemic Targets: Standards of Medical Care in Diabetes—2018Diabetes Care, 41
-
K. Khunti, A. Nikolajsen, B. Thorsted, M. Andersen, Melanie Davies, Sanjoy Paul (2016)
Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulinDiabetes, Obesity & Metabolism, 18
-
I. Stratton, A. Adler, A. Neil, D. Matthews, S. Manley, C. Cull, D. Hadden, R. Turner, R. Holman (2000)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ : British Medical Journal, 321
-
K. Khunti, D. Millar-Jones (2017)
Clinical inertia to insulin initiation and intensification in the UK: A focused literature review.Primary care diabetes, 11 1
-
(Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:100.)
Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:100.Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:100., Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:100.
-
S. Paul, K. Klein, B. Thorsted, M. Wolden, K. Khunti (2015)
Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetesCardiovascular Diabetology, 14
-
A. Stokes, S. Preston (2017)
Deaths Attributable to Diabetes in the United States: Comparison of Data Sources and Estimation ApproachesPLoS ONE, 12
-
S. Inzucchi, R. Bergenstal, J. Buse, M. Diamant, E. Ferrannini, M. Nauck, A. Peters, A. Tsapas, R. Wender, D. Matthews (2012)
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered ApproachDiabetes Care, 35
-
C. Demetrescu, Michael Kaufmann, S. Kobourov, Petra Mutzel (2011)
Graph Drawing with Algorithm Engineering Methods (Dagstuhl Seminar 11191)Dagstuhl Reports, 1
-
N. Wu, M. Aagren, L. Boulanger, M. Friedman, Kelly Wilkey (2012)
Assessing achievement and maintenance of glycemic control by patients initiating basal insulinCurrent Medical Research and Opinion, 28
-
M. Peyrot, R. Rubin, T. Lauritzen, S. Skovlund, F. Snoek, D. Matthews, R. Landgraf, L. Kleinebreil (2005)
Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study.Diabetes care, 28 11
-
W. Polonsky, S. Thompson, W. Wei, M. Riddle, S. Chaudhari, J. Jackson, A. Bruno (2014)
Greater fear of hypoglycaemia with premixed insulin than with basal‐bolus insulin glargine and glulisine: patient‐reported outcomes from a 60‐week randomised studyDiabetes, 16
-
K. Kostev, F. Dippel, W. Rathmann (2015)
Glycemic control after initiating basal insulin therapy in patients with type 2 diabetes: a primary care database analysisDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 8
-
L. Kennedy (2007)
A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 DiabetesYearbook of Endocrinology, 2007
-
Samy McFarlane (2009)
Insulin Therapy and Type 2 Diabetes: Management of Weight GainThe Journal of Clinical Hypertension, 11
-
K Hermansen, M Davies, T Derezinski, RG Martinez, P Clauson, P Home (2006)
A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetesDiabetes Care, 29
-
Oren Steen, R. Goldenberg (2017)
The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes.Canadian journal of diabetes, 41 5
-
S. Vijan, R. Hayward, D. Ronis, T. Hofer (2005)
Brief report: the burden of diabetes therapy: implications for the design of effective patient-centered treatment regimens.Journal of general internal medicine, 20 5
-
Jason Gordon, Jason Gordon, R. Pockett, A. Tetlow, P. McEwan, Philip Home (2010)
A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database studyInternational Journal of Clinical Practice, 64
-
S. Kim, N. Kim, B. Ku, H. Shon, D. Kim, T. Park, Yong-Seong Kim, I. Kim, D. Choi (2017)
Delay of insulin initiation in patients with type 2 diabetes mellitus inadequately controlled with oral hypoglycemic agents (analysis of patient‐ and physician‐related factors): A prospective observational DIPP‐FACTOR study in KoreaJournal of Diabetes Investigation, 8
-
(Centers for Disease Control. National diabetes statistics report, 2017. [article online], 2018. https://www.cdc.gov/diabetes/data/statistics-report/index.html. Accessed 22 Jan 2018.)
Centers for Disease Control. National diabetes statistics report, 2017. [article online], 2018. https://www.cdc.gov/diabetes/data/statistics-report/index.html. Accessed 22 Jan 2018.Centers for Disease Control. National diabetes statistics report, 2017. [article online], 2018. https://www.cdc.gov/diabetes/data/statistics-report/index.html. Accessed 22 Jan 2018., Centers for Disease Control. National diabetes statistics report, 2017. [article online], 2018. https://www.cdc.gov/diabetes/data/statistics-report/index.html. Accessed 22 Jan 2018.
-
Shi‐Dou Lin, S. Tsai, S. Tu, Ching-Chieh Su, Jung-Fu Chen, Chieh-hsiang Lu, Chao-Hung Wang, N. Yu, S. Hsu, M. Hsieh (2015)
Glycosylated hemoglobin level and number of oral antidiabetic drugs predict whether or not glycemic target is achieved in insulin-requiring type 2 diabetes.Primary care diabetes, 9 2
-
A. Garber, M. Abrahamson, J. Barzilay, L. Blonde, Z. Bloomgarden, Michael Bush, S. Dagogo-Jack, R. DeFronzo, D. Einhorn, V. Fonseca, J. Garber, W. Garvey, G. Grunberger, Y. Handelsman, R. Henry, I. Hirsch, P. Jellinger, J. McGill, J. Mechanick, P. Rosenblit, G. Umpierrez (2016)
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 22 1
-
S. Inzucchi, R. Bergenstal, J. Buse, M. Diamant, E. Ferrannini, M. Nauck, A. Peters, A. Tsapas, R. Wender, David Matthews, David Matthews, David Matthews (2013)
Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia, 56
-
P. Levin, Steve Zhou, Emily Durden, A. Farr, J. Gill, Wenhui Wei (2016)
Clinical and Economic Outcomes Associated With the Timing of Initiation of Basal Insulin in Patients With Type 2 Diabetes Mellitus Previously Treated With Oral Antidiabetes Drugs.Clinical therapeutics, 38 1
-
P. Dandona (2017)
Minimizing Glycemic Fluctuations in Patients with Type 2 Diabetes: Approaches and ImportanceDiabetes Technology & Therapeutics, 19
-
K. Esposito, Paolo Chiodini, G. Bellastella, M. Maiorino, D. Giugliano (2012)
Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patientsDiabetes, 14
-
Patricia Palomo-López, R. Becerro-de-Bengoa-Vallejo, M. Losa-Iglesias, David Rodríguez-Sanz, C. Calvo-Lobo, Daniel López-López (2017)
Footwear used by older people and a history of hyperkeratotic lesions on the footMedicine, 96
-
D. Mauricio, L. Meneghini, J. Seufert, L. Liao, Hongwei Wang, Liyue Tong, A. Calí, P. Stella, P. Carita, K. Khunti (2017)
Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USADiabetes, Obesity & Metabolism, 19
-
M. Dalal, M. Grabner, N. Bonine, J. Stephenson, A. Digenio, N. Bieszk (2016)
Are patients on basal insulin attaining glycemic targets? Characteristics and goal achievement of patients with type 2 diabetes mellitus treated with basal insulin and physician-perceived barriers to achieving glycemic targets.Diabetes research and clinical practice, 121
-
(2017)
National diabetes statistics report
- Publisher
- Springer Journals
- Copyright
- Copyright © 2018 by The Author(s)
- Subject
- Medicine & Public Health; Internal Medicine; Diabetes; Cardiology; Endocrinology
- ISSN
- 1869-6953
- eISSN
- 1869-6961
- DOI
- 10.1007/s13300-018-0413-5
- Publisher site
- See Article on Publisher Site
Abstract
Diabetes Ther (2018) 9:1347–1358 https://doi.org/10.1007/s13300-018-0413-5 BRIEF REPORT Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA . . . Lawrence Blonde Luigi Meneghini Xuejun Victor Peng . . . . Anders Boss Kyu Rhee Alka Shaunik Supriya Kumar . . Sidhartha Balodi Claire Brulle-Wohlhueter Rory J. McCrimmon Received: March 2, 2018 / Published online: March 29, 2018 The Author(s) 2018 least one valid glycated hemoglobin (HbA1c) ABSTRACT result recorded both within 90 days before and 720 days after BI initiation were selected. We Introduction: Basal insulin (BI) plays an estimated the changes from baseline in HbA1c important role in treating type 2 diabetes (T2D), every 6 months, the quarterly conditional especially when oral antidiabetic (OAD) medi- probabilities of reaching HbA1c \ 7% if a cations are insufficient for glycemic control. We patient had not achieved glycemic control prior conducted a retrospective, observational study to each quarter (Q), and the cumulative proba- using electronic medical records (EMR) data bility of reaching glycemic control over from the IBM Explorys database to evaluate 24 months. the probability of achieving glycemic control Results: Our cohort was representative of over 24 months after
Journal
Diabetes Therapy – Springer Journals
Published: Mar 29, 2018